BidaskClub upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a hold rating to a buy rating in a research note published on Wednesday morning.
ESPR has been the topic of several other reports. Zacks Investment Research downgraded Esperion Therapeutics from a buy rating to a hold rating in a report on Tuesday. ValuEngine upgraded Esperion Therapeutics from a buy rating to a strong-buy rating in a report on Thursday, November 1st. BTIG Research started coverage on Esperion Therapeutics in a report on Tuesday, October 16th. They set a buy rating and a $82.00 target price on the stock. Northland Securities upgraded Esperion Therapeutics from a market perform rating to an outperform rating and set a $65.00 target price on the stock in a report on Monday, October 29th. Finally, Citigroup upgraded Esperion Therapeutics from a neutral rating to a buy rating and raised their target price for the company from $57.00 to $75.00 in a report on Friday, August 17th. Two research analysts have rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. Esperion Therapeutics presently has a consensus rating of Buy and a consensus price target of $75.96.
Shares of NASDAQ:ESPR traded down $3.97 during mid-day trading on Wednesday, hitting $54.49. 933,235 shares of the company traded hands, compared to its average volume of 1,022,921. The company has a market cap of $1.58 billion, a P/E ratio of -7.81 and a beta of 2.20. Esperion Therapeutics has a 52-week low of $33.06 and a 52-week high of $82.68.
Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the consensus estimate of ($1.64) by ($0.22). During the same quarter last year, the firm posted ($1.86) earnings per share. Equities research analysts expect that Esperion Therapeutics will post -6.48 EPS for the current year.
In other Esperion Therapeutics news, Director Roger S. Newton sold 7,300 shares of Esperion Therapeutics stock in a transaction that occurred on Friday, August 17th. The stock was sold at an average price of $50.06, for a total transaction of $365,438.00. Following the sale, the director now directly owns 616,426 shares in the company, valued at approximately $30,858,285.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Boxer Capital, Llc sold 100,000 shares of Esperion Therapeutics stock in a transaction that occurred on Monday, November 5th. The stock was sold at an average price of $56.38, for a total value of $5,638,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 177,327 shares of company stock worth $9,732,065 over the last 90 days. 32.50% of the stock is owned by company insiders.
Hedge funds have recently bought and sold shares of the business. Opera Trading Capital purchased a new stake in Esperion Therapeutics during the 3rd quarter worth approximately $173,000. Xact Kapitalforvaltning AB bought a new stake in shares of Esperion Therapeutics in the 1st quarter valued at approximately $250,000. Keybank National Association OH increased its holdings in shares of Esperion Therapeutics by 97.7% in the 2nd quarter. Keybank National Association OH now owns 7,663 shares of the biopharmaceutical company’s stock valued at $300,000 after acquiring an additional 3,787 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its holdings in shares of Esperion Therapeutics by 40.6% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 7,698 shares of the biopharmaceutical company’s stock valued at $302,000 after acquiring an additional 2,224 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Esperion Therapeutics in the 2nd quarter valued at approximately $333,000.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Featured Story: How to Use a Moving Average for Trading
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.